Sato, Y., Sakaguchi, S., Takechi, K., Chuma, M., Yagi, K., Kane, C., Goda, M., Hamano, H., Aoe, Y., Nokihara, H., Kubo, Y., Hashimoto, I., & Yanagawa, H. (2022). Trends in Investigator-Initiated Clinical Studies at a University Hospital after Enforcement of the 2018 Clinical Trials Act in Japan. Biological and Pharmaceutical Bulletin, 45(3), 374-377. doi:10.1248/bpb.b21-00753
Kane, C., Sakaguchi, S., Chuma, M., Yagi, K., Takechi, K., Aoe, Y., Takagai, T., & Yanagawa, H. (2022). Research Ethics Consultation in Nursing Studies. J Empir Res Hum Res Ethics, 17(1-2), 63-69. doi:10.1177/15562646211036577
Yagi, K., Sato, Y., Sakaguchi, S., Goda, M., Hamano, H., Aizawa, F., Shimizu, M., Inoue-Hamano, A., Nishimori, T., Tagi, M., Kanno, M., Matsuoka-Ando, R., Yoshioka, T., Matstubara, Y., Izawa-Ishizawa, Y., Shimizu, R., Maruo, A., Kuniki, Y., Sakamoto, Y., Itobayashi, S., Zamami, Y., Yanagawa, H., & Ishizawa, K. (2022). A web-based survey of educational opportunities of medical professionals based on changes in conference design during the COVID-19 pandemic. Educ Inf Technol (Dordr), 1-16. doi:10.1007/s10639-022-11032-5
Yanagawa, H., Chuma, M., Takechi, K., Yagi, K., Sato, Y., Kane, C., Sakaguchi, S., Doi, K., Inoue, Y., & Matsui, K. (2021). An educational workshop designed for research ethics consultants to educate investigators on ethical considerations. International Journal of Ethics Education, 6(1), 87-96. doi:10.1007/s40889-020-00107-x
Matsui, K., Inoue, Y., Yanagawa, H., & Takano, T. (2021). A Proposed Model of Core Competencies for Research Ethics Consultants. Asian Bioethics Review, 13(3), 355-370. doi:10.1007/s41649-021-00178-y
Chuma, M., Takechi, K., Yagi, K., Sakaguchi, S., Nokihara, H., Kane, C., Sato, Y., Niimura, T., Goda, M., Zamami, Y., Ishizawa, K., & Yanagawa, H. (2021). Academic investigators’ interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act. The Journal of Medical Investigation, 68(1.2), 71-75. doi:10.2152/jmi.68.71
Yagi, K., Maeda, K., Sakaguchi, S., Chuma, M., Sato, Y., Kane, C., Akaishi, A., Ishizawa, K., & Yanagawa, H. (2020). Status of Institutional Review Board Meetings Conducted Through Web Conference Systems in Japanese National University Hospitals During the COVID-19 Pandemic: Questionnaire Study. Journal of medical Internet research, 22(11), e22302-e22302. doi:10.2196/22302
Haji, S., Fujita, K., Oki, R., Osaki, Y., Miyamoto, R., Morino, H., Nagano, S., Atsuta, N., Kanazawa, Y., Matsumoto, Y., Arisawa, A., Kawai, H., Sato, Y., Sakaguchi, S., Yagi, K., Hamatani, T., Kagimura, T., Yanagawa, H., Mochizuki, H., Doyu, M., Sobue, G., Harada, M., & Izumi, Y. (2023). An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study. JMIR research protocols, 12, e42032. doi:10.2196/42032
Oki, R., Izumi, Y., Fujita, K., Miyamoto, R., Nodera, H., Sato, Y., Sakaguchi, S., Nokihara, H., Kanai, K., Tsunemi, T., Hattori, N., Hatanaka, Y., Sonoo, M., Atsuta, N., Sobue, G., Shimizu, T., Shibuya, K., Ikeda, K., Kano, O., Nishinaka, K., Kojima, Y., Oda, M., Komai, K., Kikuchi, H., Kohara, N., Urushitani, M., Nakayama, Y., Ito, H., Nagai, M., Nishiyama, K., Kuzume, D., Shimohama, S., Shimohata, T., Abe, K., Ishihara, T., Onodera, O., Isose, S., Araki, N., Morita, M., Noda, K., Toda, T., Maruyama, H., Furuya, H., Teramukai, S., Kagimura, T., Noma, K., Yanagawa, H., Kuwabara, S., & Kaji, R. (2022). Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA neurology. doi:10.1001/jamaneurol.2022.0901
Sakurada, T., Nokihara, H., Koga, T., Zamami, Y., Goda, M., Yagi, K., Hamano, H., Aizawa, F., Ogino, H., Sato, S., Kirino, Y., Goto, H., Nishioka, Y., & Ishizawa, K. (2022). Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study. Oncologist. doi:10.1093/oncolo/oyab077
Savarirayan, R., Tofts, L., Irving, M., Wilcox, W., Bacino, C. A., Hoover-Fong, J., Ullot Font, R., Harmatz, P., Rutsch, F., Bober, M. B., Polgreen, L. E., Ginebreda, I., Mohnike, K., Charrow, J., Hoernschemeyer, D., Ozono, K., Alanay, Y., Arundel, P., Kagami, S., Yasui, N., White, K. K., Saal, H. M., Leiva-Gea, A., Luna-González, F., Mochizuki, H., Basel, D., Porco, D. M., Jayaram, K., Fisheleva, E., Huntsman-Labed, A., & Day, J. (2020). Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. The Lancet, 396(10252), 684-692. doi:10.1016/S0140-6736(20)31541-5
Okahisa, T., Sogabe, M., Nakagawa, T., Tanaka, K., Tomonari, T., Taniguchi, T., Takahashi, A., Kinouchi, Y., Nishioka, J., Igata, N., Yanagawa, H., Komatsu, T., Ohnishi, Y., Fukuhara, M., Ishikawa, M., Shibata, H., Shinomiya, H., Nakasono, M., Kishi, F., Komai, K., Tatsuki, Y., Murashima, T., Deguchi, Y., Aramaki, H., Fukumitsu, H., & Takayama, T. (2020). Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy. Artif Organs, 44(8), 856-872. doi:10.1111/aor.13681
Chan, M. L., Qi, Y., Larimore, K., Cherukuri, A., Seid, L., Jayaram, K., Jeha, G., Fisheleva, E., Day, J., Huntsman-Labed, A., Savarirayan, R., Irving, M., Bacino, C. A., Hoover-Fong, J., Ozono, K., Mohnike, K., Wilcox, W. R., Horton, W. A., & Henshaw, J. (2022). Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet, 61(2), 263-280. doi:10.1007/s40262-021-01059-1
Agarwal, N., Azad, A., Shore, N. D., Carles, J., Fay, A. P., Dunshee, C., Karsh, L. I., Paccagnella, M. L., Santo, N. D., Elmeliegy, M., Lin, X., Czibere, A., & Fizazi, K. (2022). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol, 18(4), 425-436. doi:10.2217/fon-2021-0811
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C. K., Gurney, H., Grimm, M. O., Tomita, Y., Castellano, D., Rini, B. I., Choueiri, T. K., Leung, D., Saggi, S. S., Lee, C. W., McHenry, M. B., & Motzer, R. J. (2022). First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol, 81(3), 266-271. doi:10.1016/j.eururo.2021.10.001
Ishihara, O., Nelson, S. M., & Arce, J. C. (2022). Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients. Reprod Biomed Online, 44(1), 177-184. doi:10.1016/j.rbmo.2021.09.014
Motzer, R. J., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Shah, A. Y., Suárez, C., Hamzaj, A., Porta, C., Hocking, C. M., Kessler, E. R., Gurney, H., Tomita, Y., Bedke, J., Zhang, J., Simsek, B., Scheffold, C., Apolo, A. B., & Choueiri, T. K. (2022). Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol, 23(7), 888-898. doi:10.1016/s1470-2045(22)00290-x
Mikami, T., Hirabayashi, K., Okawa, K., Betsuyaku, T., Watanabe, S., Imamura, Y., Tanizawa, K., Hayashi, T., Akao, M., Yamashita, T., & Okumura, K. (2022). Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial. J Am Heart Assoc, 11(17), e024970. doi:10.1161/jaha.122.024970
Wykoff, C. C., Abreu, F., Adamis, A. P., Basu, K., Eichenbaum, D. A., Haskova, Z., Lin, H., Loewenstein, A., Mohan, S., Pearce, I. A., Sakamoto, T., Schlottmann, P. G., Silverman, D., Sun, J. K., Wells, J. A., Willis, J. R., & Tadayoni, R. (2022). Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet, 399(10326), 741-755. doi:10.1016/s0140-6736(22)00018-6
Ton, T. G. N., Pal, N., Trinh, H., Mahrus, S., Bretscher, M. T., Machado, R. J. M., Sadetsky, N., Chaudhary, N., Lu, M. W., & Riely, G. J. (2022). Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res, 28(13), 2844-2853. doi:10.1158/1078-0432.Ccr-22-0471
Bullich, S., Mueller, A., De Santi, S., Koglin, N., Krause, S., Kaplow, J., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., Scott, D., Gee, M., Stephens, A., & Irizarry, M. (2022). Evaluation of tau deposition using (18)F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study. Alzheimers Res Ther, 14(1), 105. doi:10.1186/s13195-022-01048-x
Tomita, Y., Yamamoto, Y., Tsuchiya, N., Kanayama, H., Eto, M., Miyake, H., Powles, T., Yoshida, M., Koide, Y., Umeyama, Y., di Pietro, A., & Uemura, H. (2022). Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. Int J Clin Oncol, 27(2), 383-395. doi:10.1007/s10147-021-02067-8
Cella, D., Motzer, R. J., Suarez, C., Blum, S. I., Ejzykowicz, F., Hamilton, M., Wallace, J. F., Simsek, B., Zhang, J., Ivanescu, C., Apolo, A. B., & Choueiri, T. K. (2022). Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol, 23(2), 292-303. doi:10.1016/s1470-2045(21)00693-8
Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Gurney, H., Kollmannsberger, C. K., Grimm, M. O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B. I., McHenry, M. B., Lee, C. W., McCarthy, J., Ejzykowicz, F., & Tannir, N. M. (2022). Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128(11), 2085-2097. doi:10.1002/cncr.34180
Kimura, N., Kawahara, T., Uemura, Y., Atsumi, T., Sumida, T., Mimura, T., Kawaguchi, Y., Amano, H., Iwasaki, Y., Kaneko, Y., Matsui, T., Muro, Y., Imura, Y., Kanda, T., Tanaka, Y., Kawakami, A., Jinnin, M., Ishii, T., Hiromura, K., Miwa, Y., Nakajima, H., Kuwana, M., Nishioka, Y., Morinobu, A., Kameda, H., & Kohsaka, H. (2022). Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-center, randomized controlled trial. Rheumatology (Oxford). doi:10.1093/rheumatology/keac101
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., Ye, D., Parnis, F., Cruz, F., Tammela, T. L. J., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., Maughan, B. L., Joensuu, H., Thiele, S., Li, R., Kuss, I., & Tombal, B. (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med, 386(12), 1132-1142. doi:10.1056/NEJMoa2119115
Kuroda, M., Tamiya, E., Nose, T., Ogimoto, A., Taura, J., Imamura, Y., Fukuzawa, M., Hayashi, T., Akao, M., Yamashita, T., Lip, G. Y. H., & Okumura, K. (2022). Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial. JAMA Cardiol, 7(6), 583-590. doi:10.1001/jamacardio.2022.0480
Chowdhury, S., Oudard, S., Uemura, H., Joniau, S., Dearden, L., Capone, C., Van Sanden, S., Diels, J., & Hadaschik, B. A. (2022). Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. Adv Ther, 39(1), 518-531. doi:10.1007/s12325-021-01885-6
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, D., Manarite, J., Muslin, D., Farrington, T., & Tombal, B. (2022). Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. Future Oncol, 18(21), 2585-2597. doi:10.2217/fon-2022-0433
Labriola, M. K., & George, D. J. (2022). Setting a new standard for long-term survival in metastatic kidney cancer. Cancer, 128(11), 2058-2060. doi:10.1002/cncr.34177
Sandborn, W. J., D'Haens, G. R., Reinisch, W., Panés, J., Chan, D., Gonzalez, S., Weisel, K., Germinaro, M., Frustaci, M. E., Yang, Z., Adedokun, O. J., Han, C., Panaccione, R., Hisamatsu, T., Danese, S., Rubin, D. T., Sands, B. E., Afzali, A., Andrews, J. M., & Feagan, B. G. (2022). Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology, 162(6), 1650-1664.e1658. doi:10.1053/j.gastro.2022.01.047
Lu, S., Fang, J., Wang, Z., Fan, Y., Liu, Y., He, J., Zhou, J., Hu, J., Xia, J., Liu, W., Shi, J., Yi, J., & Cao, L. (2022). Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer medicine. doi:10.1002/cam4.5144
Motzer, R. J., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Alekseev, B. Y., Lee, J. L., Suarez, C., Stroyakovskiy, D., De Giorgi, U., Donskov, F., Mellado, B., Banchereau, R., Hamidi, H., Khan, O., Craine, V., Huseni, M., Flinn, N., Dubey, S., & Rini, B. I. (2022). Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol, 8(2), 275-280. doi:10.1001/jamaoncol.2021.5981
Yoshida, T., Nakamura, A., Funada, J., Amino, M., Shimizu, W., Fukuzawa, M., Watanabe, S., Hayashi, T., Yamashita, T., Okumura, K., & Akao, M. (2022). Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial. Circulation, 145(9), 718-720. doi:10.1161/circulationaha.121.057190
Rini, B. I., Atkins, M. B., Plimack, E. R., Soulières, D., McDermott, R. S., Bedke, J., Tartas, S., Alekseev, B., Melichar, B., Shparyk, Y., Kondoh, C., Langiewicz, P., Wood, L. A., Hammers, H., Silber, C. G., Haber, B., Jensen, E., Chen, M., & Powles, T. (2022). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. Eur Urol Oncol, 5(2), 225-234. doi:10.1016/j.euo.2021.05.007
Hamuro, L., Hu, Z., Passarell, J., Barcomb, H., Zhang, J., Goldstein, S., Bello, A., Roy, A., & Zhu, L. (2022). Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma. Clin Cancer Res, 28(8), 1603-1613. doi:10.1158/1078-0432.Ccr-21-3149
Hata, A., Okamoto, I., Inui, N., Okada, M., Morise, M., Akiyoshi, K., Takeda, M., Watanabe, Y., Sugawara, S., Shinagawa, N., Kubota, K., Saeki, T., & Tamura, T. (2022). Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol, 40(2), 180-188. doi:10.1200/jco.21.01315
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., Lai, T. Y. Y., Silverman, D., Regillo, C., Swaminathan, B., Viola, F., Cheung, C. M. G., & Wong, T. Y. (2022). Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet, 399(10326), 729-740. doi:10.1016/s0140-6736(22)00010-1
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulovic, S., Demey, W., Ullén, A., Loriot, Y., Sridhar, S. S., Tsuchiya, N., Kopyltsov, E., Sternberg, C. N., Bellmunt, J., Aragon-Ching, J. B., Petrylak, D. P., Laliberte, R. J., Huang, B., Costa, N., Blake-Haskins, J. A., & Grivas, P. (2022). Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future Oncol, 18(19), 2361-2371. doi:10.2217/fon-2021-1631
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., Srinivas, S., Merchan, J. R., McKay, R. R., Petrylak, D. P., Sasse, C., Moreno, B. H., Yu, Y., Carret, A. S., & Rosenberg, J. E. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol, Jco2201643. doi:10.1200/jco.22.01643
Masters, J. C., Khandelwal, A., di Pietro, A., Dai, H., & Brar, S. (2022). Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT Pharmacometrics Syst Pharmacol, 11(4), 458-468. doi:10.1002/psp4.12771
Pal, S. K., Uzzo, R., Karam, J. A., Master, V. A., Donskov, F., Suarez, C., Albiges, L., Rini, B., Tomita, Y., Kann, A. G., Procopio, G., Massari, F., Zibelman, M., Antonyan, I., Huseni, M., Basu, D., Ci, B., Leung, W., Khan, O., Dubey, S., & Bex, A. (2022). Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. doi:10.1016/s0140-6736(22)01658-0
Husni, R. E., Ngo, L. Y., Senokuchi, H., Patten, A., Hiramatsu, H., Watanabe, K., & Yamamoto, T. (2022). Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM). Epilepsia Open, 7(1), 59-66. doi:10.1002/epi4.12551
Motzer, R., Porta, C., Alekseev, B., Rha, S. Y., Choueiri, T. K., Mendez-Vidal, M. J., Hong, S. H., Kapoor, A., Goh, J. C., Eto, M., Bennett, L., Wang, J., Pan, J. J., Saretsky, T. L., Perini, R. F., He, C. S., Mody, K., & Cella, D. (2022). Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol, 23(6), 768-780. doi:10.1016/s1470-2045(22)00212-1
Solomon, B. J., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., & Shaw, A. T. (2021). Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncol, 17(34), 4649-4656. doi:10.2217/fon-2021-0904
Amato, A. A., Hanna, M. G., Machado, P. M., Badrising, U. A., Chinoy, H., Benveniste, O., Karanam, A. K., Wu, M., Tankó, L. B., Schubert-Tennigkeit, A. A., Papanicolaou, D. A., Lloyd, T. E., Needham, M., Liang, C., Reardon, K. A., de Visser, M., Ascherman, D. P., Barohn, R. J., Dimachkie, M. M., Miller, J. A. L., Kissel, J. T., Oskarsson, B., Joyce, N. C., Van den Bergh, P., Baets, J., De Bleecker, J. L., Karam, C., David, W. S., Mirabella, M., Nations, S. P., Jung, H. H., Pegoraro, E., Maggi, L., Rodolico, C., Filosto, M., Shaibani, A. I., Sivakumar, K., Goyal, N. A., Mori-Yoshimura, M., Yamashita, S., Suzuki, N., Aoki, M., Katsuno, M., Morihata, H., Murata, K., Nodera, H., Nishino, I., Romano, C. D., Williams, V. S. L., Vissing, J., & Zhang Auberson, L. (2021). Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology, 96(12), e1595-e1607. doi:10.1212/wnl.0000000000011626
Yokoyama, O., Honda, M., Yamanishi, T., Sekiguchi, Y., Fujii, K., Kinoshita, K., Nakayama, T., Ueno, A., & Mogi, T. (2021). Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial. Int Urol Nephrol, 53(11), 2243-2250. doi:10.1007/s11255-021-02962-z
Choueiri, T. K., Larkin, J., Pal, S., Motzer, R. J., Rini, B. I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M. A., Hariharan, S., Chudnovsky, A., Ching, K. A., Mu, X. J., Mariani, M., Robbins, P. B., Huang, B., di Pietro, A., & Albiges, L. (2021). Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open, 6(3), 100101. doi:10.1016/j.esmoop.2021.100101
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., Suárez, C., Hamzaj, A., Goh, J. C., Barrios, C., Richardet, M., Porta, C., Kowalyszyn, R., Feregrino, J. P., Żołnierek, J., Pook, D., Kessler, E. R., Tomita, Y., Mizuno, R., Bedke, J., Zhang, J., Maurer, M. A., Simsek, B., Ejzykowicz, F., Schwab, G. M., Apolo, A. B., & Motzer, R. J. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 384(9), 829-841. doi:10.1056/NEJMoa2026982
Galsky, M. D., Hoimes, C. J., Necchi, A., Shore, N., Witjes, J. A., Steinberg, G., Bedke, J., Nishiyama, H., Fang, X., Kataria, R., Sbar, E., Jia, X., & Siefker-Radtke, A. (2021). Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol, 17(24), 3137-3150. doi:10.2217/fon-2021-0273
Garon, E. B., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M. J., Robinet, G., Le Moulec, S., Natale, R., Schneider, J., Shepherd, F. A., Garassino, M. C., Geater, S. L., Szekely, Z. P., Van Ngoc, T., Liu, F., Scheuring, U., Patel, N., Peters, S., & Rizvi, N. A. (2021). Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer, 22(4), 301-312.e308. doi:10.1016/j.cllc.2021.02.010
Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Garassino, M. C., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Thiyagarajah, P., Jiang, H., & Paz-Ares, L. (2021). Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 22(1), 51-65. doi:10.1016/s1470-2045(20)30539-8
Honda, M., Yokoyama, O., Takahashi, R., Matsuda, T., Nakayama, T., & Mogi, T. (2021). Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension. Int J Urol, 28(9), 906-912. doi:10.1111/iju.14602
Ishihara, O., & Arce, J. C. (2021). Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online, 42(5), 909-918. doi:10.1016/j.rbmo.2021.01.023
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., Lu, J., Schönland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., Hungria, V., Wong, S. W., Rosenzweig, M., Bumma, N., Huart, A., Dimopoulos, M. A., Bhutani, D., Waxman, A. J., Goodman, S. A., Zonder, J. A., Lam, S., Song, K., Hansen, T., Manier, S., Roeloffzen, W., Jamroziak, K., Kwok, F., Shimazaki, C., Kim, J. S., Crusoe, E., Ahmadi, T., Tran, N., Qin, X., Vasey, S. Y., Tromp, B., Schecter, J. M., Weiss, B. M., Zhuang, S. H., Vermeulen, J., Merlini, G., & Comenzo, R. L. (2021). Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med, 385(1), 46-58. doi:10.1056/NEJMoa2028631
Marconi, L., Sun, M., Beisland, C., Klatte, T., Ljungberg, B., Stewart, G. D., Dabestani, S., Choueiri, T. K., & Bex, A. (2021). Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer, 19(2), e92-e99. doi:10.1016/j.clgc.2020.12.005
Matsuoka, K., Naganuma, M., Hibi, T., Tsubouchi, H., Oketani, K., Katsurabara, T., Hojo, S., Takenaka, O., Kawano, T., Imai, T., & Kanai, T. (2021). Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease. J Gastroenterol Hepatol, 36(8), 2180-2186. doi:10.1111/jgh.15463
Motzer, R., Alekseev, B., Rha, S. Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S. H., Kapoor, A., Alonso Gordoa, T., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., Kim, M., Gurney, H., Patel, V., Peer, A., Procopio, G., Takagi, T., Melichar, B., Rolland, F., De Giorgi, U., Wong, S., Bedke, J., Schmidinger, M., Dutcus, C. E., Smith, A. D., Dutta, L., Mody, K., Perini, R. F., Xing, D., & Choueiri, T. K. (2021). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med, 384(14), 1289-1300. doi:10.1056/NEJMoa2035716
Taylor, M. H., Schmidt, E. V., Dutcus, C., Pinheiro, E. M., Funahashi, Y., Lubiniecki, G., & Rasco, D. (2021). The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol, 17(6), 637-648. doi:10.2217/fon-2020-0937
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., Fléchon, A., Gunduz, S., Loriot, Y., Rodriguez-Vida, A., Mamtani, R., Yu, E. Y., Nam, K., Imai, K., Homet Moreno, B., & Alva, A. (2021). Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol, 22(7), 931-945. doi:10.1016/s1470-2045(21)00152-2
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J. L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., Campbell, M., Matsangou, M., & Petrylak, D. P. (2021). Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med, 384(12), 1125-1135. doi:10.1056/NEJMoa2035807
Powles, T., Sridhar, S. S., Loriot, Y., Bellmunt, J., Mu, X. J., Ching, K. A., Pu, J., Sternberg, C. N., Petrylak, D. P., Tambaro, R., Dourthe, L. M., Alvarez-Fernandez, C., Aarts, M., di Pietro, A., Grivas, P., & Davis, C. B. (2021). Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med, 27(12), 2200-2211. doi:10.1038/s41591-021-01579-0
Rini, B. I., Atkins, M. B., Choueiri, T. K., Thomaidou, D., Rosbrook, B., Thakur, M., & Hutson, T. E. (2021). Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer, 19(5), e306-e312. doi:10.1016/j.clgc.2021.03.019
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C. K., Gurney, H., Grimm, M. O., Tomita, Y., Castellano, D., Rini, B. I., Choueiri, T. K., Saggi, S. S., McHenry, M. B., & Motzer, R. J. (2020). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 5(6), e001079. doi:10.1136/esmoopen-2020-001079
Ambavane, A., Yang, S., Atkins, M. B., Rao, S., Shah, A., Regan, M. M., McDermott, D. F., & Michaelson, M. D. (2020). Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. Immunotherapy, 12(1), 37-51. doi:10.2217/imt-2019-0199
Okumura, K., Akao, M., Yoshida, T., Kawata, M., Okazaki, O., Akashi, S., Eshima, K., Tanizawa, K., Fukuzawa, M., Hayashi, T., Akishita, M., Lip, G. Y. H., & Yamashita, T. (2020). Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med, 383(18), 1735-1745. doi:10.1056/NEJMoa2012883
Smith, M. R., Mehra, M., Nair, S., Lawson, J., & Small, E. J. (2020). Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer, 18(2), e180-e189. doi:10.1016/j.clgc.2019.10.030
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., & Solomon, B. J. (2020). First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med, 383(21), 2018-2029. doi:10.1056/NEJMoa2027187
Palladini, G., Kastritis, E., Maurer, M. S., Zonder, J., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Bumma, N., Kaufman, J. L., Medvedova, E., Kovacsovics, T., Rosenzweig, M., Sanchorawala, V., Qin, X., Vasey, S. Y., Weiss, B. M., Vermeulen, J., Merlini, G., & Comenzo, R. L. (2020). Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 136(1), 71-80. doi:10.1182/blood.2019004460
Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M. O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., & Albiges, L. (2020). Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol, 31(8), 1030-1039. doi:10.1016/j.annonc.2020.04.010
Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., Alekseev, B., Gravis, G., Campbell, M. T., Penkov, K., Lee, J. L., Hariharan, S., Wang, X., Zhang, W., Wang, J., Chudnovsky, A., di Pietro, A., Donahue, A. C., & Choueiri, T. K. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med, 26(11), 1733-1741. doi:10.1038/s41591-020-1044-8
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., Loriot, Y., Sridhar, S. S., Tsuchiya, N., Kopyltsov, E., Sternberg, C. N., Bellmunt, J., Aragon-Ching, J. B., Petrylak, D. P., Laliberte, R., Wang, J., Huang, B., Davis, C., Fowst, C., Costa, N., Blake-Haskins, J. A., di Pietro, A., & Grivas, P. (2020). Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 383(13), 1218-1230. doi:10.1056/NEJMoa2002788
Hofmann, F., Hwang, E. C., Lam, T. B., Bex, A., Yuan, Y., Marconi, L. S., & Ljungberg, B. (2020). Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev, 10(10), Cd012796. doi:10.1002/14651858.CD012796.pub2
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., Azevedo, S. J., Borchiellini, D., McDermott, R. S., Bedke, J., Tamada, S., Yin, L., Chen, M., Molife, L. R., Atkins, M. B., & Rini, B. I. (2020). Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol, 21(12), 1563-1573. doi:10.1016/s1470-2045(20)30436-8
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., George, S., Grünwald, V., Porta, C., Neiman, V., Ravaud, A., Choueiri, T. K., Rini, B. I., Salman, P., Kollmannsberger, C. K., Tykodi, S. S., Grimm, M. O., Gurney, H., Leibowitz-Amit, R., Geertsen, P. F., Amin, A., Tomita, Y., McHenry, M. B., Saggi, S. S., & Tannir, N. M. (2020). Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer, 8(2). doi:10.1136/jitc-2020-000891
Abo, M., Shigematsu, T., Hara, H., Matsuda, Y., Nimura, A., Yamashita, Y., & Takahashi, K. (2020). Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase. Toxins (Basel), 12(2). doi:10.3390/toxins12020127
Uemura, H., Koroki, Y., Iwaki, Y., Imanaka, K., Kambara, T., Lopez-Gitlitz, A., Smith, A., & Uemura, H. (2020). Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol, 20(1), 139. doi:10.1186/s12894-020-00689-0
Hack, S. P., Spahn, J., Chen, M., Cheng, A. L., Kaseb, A., Kudo, M., Lee, H. C., Yopp, A., Chow, P., & Qin, S. (2020). IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol, 16(15), 975-989. doi:10.2217/fon-2020-0162
Tomita, Y., Kondo, T., Kimura, G., Inoue, T., Wakumoto, Y., Yao, M., Sugiyama, T., Oya, M., Fujii, Y., Obara, W., Motzer, R. J., & Uemura, H. (2020). Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Jpn J Clin Oncol, 50(1), 12-19. doi:10.1093/jjco/hyz132
Senan, S., Okamoto, I., Lee, G. W., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N., Jiang, H., & Cho, B. C. (2020). Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clin Lung Cancer, 21(2), e84-e88. doi:10.1016/j.cllc.2019.12.006
Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M. J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., Moiseyenko, V., Antonia, S. J., Le Moulec, S., Robinet, G., Natale, R., Schneider, J., Shepherd, F. A., Geater, S. L., Garon, E. B., Kim, E. S., Goldberg, S. B., Nakagawa, K., Raja, R., Higgs, B. W., Boothman, A. M., Zhao, L., Scheuring, U., Stockman, P. K., Chand, V. K., & Peters, S. (2020). Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol, 6(5), 661-674. doi:10.1001/jamaoncol.2020.0237
Tomita, Y., Tatsugami, K., Nakaigawa, N., Osawa, T., Oya, M., Kanayama, H., Nakayama Kondoh, C., Sassa, N., Nishimura, K., Nozawa, M., Masumori, N., Miyoshi, Y., Kuroda, S., Tanaka, S., Kimura, A., & Tamada, S. (2020). Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. Int J Urol, 27(11), 952-959. doi:10.1111/iju.14329
Atkins, M. B., Rini, B. I., Motzer, R. J., Powles, T., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Gurney, H., Oudard, S., Uemura, M., Lam, E. T., Grüllich, C., Quach, C., Carroll, S., Ding, B., Zhu, Q. C., Piault-Louis, E., Schiff, C., & Escudier, B. (2020). Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res, 26(11), 2506-2514. doi:10.1158/1078-0432.Ccr-19-2838
Yokoyama, O., Honda, M., Yamanishi, T., Sekiguchi, Y., Fujii, K., Nakayama, T., & Mogi, T. (2020). OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). Int J Urol, 27(3), 227-234. doi:10.1111/iju.14176
三協商事
